# Nitrocamptothecin in Treating Patients With Metastatic Melanoma

> **NCT00005875** · PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** rubitecan

## Key facts

- **NCT ID:** NCT00005875
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005875, "Nitrocamptothecin in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*